---
id: 122
title: Aspergillus Species and Invasive Aspergillosis
category: organisms
subcategory: fungi
tags: [Aspergillus, aspergillosis, voriconazole, galactomannan, halo-sign, ABPA]
difficulty: medium
---

## Question

How is invasive aspergillosis managed? Use the **"Voriconazole First-Line, Galactomannan/β-D-Glucan, Halo Sign"** framework.

## Answer

### ***Aspergillus* Syndromes:**

| Syndrome | Host | Presentation | Treatment |
|----------|------|--------------|-----------|
| **Invasive Pulmonary Aspergillosis (IPA)** | **Neutropenic**, HSCT, SOT, prolonged corticosteroids | **Fever unresponsive to antibiotics**, nodular infiltrates, **"halo sign"** (early), **"air-crescent sign"** (late) | **Voriconazole 6 mg/kg IV q12h × 2 → 4 mg/kg q12h** |
| **Chronic Pulmonary Aspergillosis (CPA)** | **Chronic lung disease** (TB, COPD), cavitary disease | **Chronic cough**, weight loss, hemoptysis, **aspergilloma** (fungus ball) | **Voriconazole** OR **itraconazole** × 6-12 months OR **surgery** (if hemoptysis) |
| **Allergic Bronchopulmonary Aspergillosis (ABPA)** | **Asthma**, **cystic fibrosis** | **Wheezing**, eosinophilia, ↑IgE, central bronchiectasis | **Prednisone** + **itraconazole** (reduces steroid dose) |
| **Aspergilloma** | Pre-existing cavity (TB, sarcoidosis) | **Hemoptysis** (chronic, can be massive) | **Surgery** (if massive hemoptysis) OR observation |

### **Invasive Aspergillosis (IA) Treatment:**

**First-Line:**
- **Voriconazole** 6 mg/kg IV q12h × 2 doses → **4 mg/kg IV q12h** (or 200-300mg PO BID)
- **Duration:** ≥6-12 weeks (until resolution of immunosuppression + radiographic improvement)

**Alternatives (if intolerant or refractory):**
- **Isavuconazole** 372mg IV/PO q8h × 6 doses → **372mg daily** (fewer drug interactions than voriconazole)
- **Liposomal amphotericin B** 3-5 mg/kg IV daily (if azole-intolerant or resistant)
- **Posaconazole** 300mg IV/PO BID × 1 day → 300mg daily (salvage therapy)

**Combination Therapy (salvage, refractory):**
- **Voriconazole + echinocandin** (caspofungin, micafungin)

### **Diagnosis:**

**Imaging:**
- **CT chest:** Nodular infiltrates, **"halo sign"** (ground-glass surrounding nodule, early <1 week), **"air-crescent sign"** (late, 2-3 weeks, cavitation)

**Microbiologic:**
- **Galactomannan** (serum, BAL): Sensitivity 70-90% (lower if on mold-active prophylaxis), **false positives** (piperacillin-tazobactam, plasma-lyte)
- **β-D-glucan** (serum): Less specific (positive with *Candida*, *Pneumocystis*), false positives (hemodialysis, IVIG, gauze)
- **Culture:** BAL, tissue biopsy (gold standard) - **septate hyphae with acute-angle branching**
- **PCR:** Emerging (high sensitivity)

**Biopsy:**
- **Histopathology:** **Septate hyphae, acute-angle (45°) branching**, tissue invasion

## Key Points

### **Risk Factors for Invasive Aspergillosis:**
- **Prolonged neutropenia** (ANC <500 × >10 days)
- **Hematopoietic stem cell transplant (HSCT)** - especially allogeneic
- **Solid organ transplant** (lung > heart-lung > liver > kidney)
- **Prolonged corticosteroids** (>3 weeks at ≥0.3 mg/kg/day)
- **Advanced HIV** (CD4 <50), but less common than *Pneumocystis*/*Cryptococcus*
- **Chronic granulomatous disease** (CGD)

### **Voriconazole Monitoring:**
- **TDM (therapeutic drug monitoring):** Target trough **1-5.5 mcg/mL** (toxicity >5.5)
- **Adverse effects:** Visual disturbances (30%), hepatotoxicity, phototoxicity, QT prolongation
- **Drug interactions:** CYP2C19/3A4 (numerous interactions)

### **ABPA (Allergic Bronchopulmonary Aspergillosis):**
- **Host:** Asthma or cystic fibrosis
- **Hypersensitivity reaction** (not invasive infection)
- **Diagnostic criteria:** Asthma + ↑IgE (>1000 IU/mL) + eosinophilia + *Aspergillus* IgE/IgG + central bronchiectasis
- **Treatment:** **Prednisone 0.5 mg/kg/day × 2 weeks** → taper + **itraconazole 200mg BID** (steroid-sparing)

### **Chronic Pulmonary Aspergillosis:**
- **Aspergilloma (fungus ball):** Mass of hyphae in pre-existing cavity
- **Hemoptysis:** Most common symptom (can be life-threatening)
- **Treatment:** **Surgery** (if massive hemoptysis or symptomatic) OR **voriconazole/itraconazole** (if unable to operate)

### **Clinical Pearls:**
- **Voriconazole** first-line for invasive aspergillosis (monitor levels, target 1-5.5 mcg/mL)
- **Halo sign** (early, <1 week), **air-crescent sign** (late, 2-3 weeks)
- **Galactomannan** useful (false positives with pip-tazo)
- **ABPA:** Asthma + ↑IgE + eosinophilia → prednisone + itraconazole
- **Aspergilloma:** Surgery if massive hemoptysis
- **Duration:** ≥6-12 weeks (until immunosuppression resolved + radiographic improvement)

## Sources

- [IDSA: Aspergillosis Guidelines 2024]
- [ECIL: Invasive Fungal Infections 2023]

## Media

N/A
